Literature DB >> 12937142

Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.

Peter Schraml1, Alexander Hergovich, Florian Hatz, Mahul B Amin, So D Lim, Wilhelm Krek, Michael J Mihatsch, Holger Moch, Alexander Hergovitz.   

Abstract

Alterations of the von Hippel-Lindau tumor-suppressor gene (VHL) on 3p25-p26 are frequent in clear-cell renal-cell carcinoma (RCC). The VHL protein (pVHL) is implicated in cell-cycle control and gene regulation, and requires transcription-dependent nuclear-cytoplasmic trafficking for its function. There are two biologically active VHL protein isoforms: pVHL(30) and pVHL(19). To study prevalence, subcellular expression and biological significance of pVHL in renal tumors, tissue microarrays with renal-cell carcinomas were immunohistochemically examined for pVHL expression. Antibodies against both protein isoforms (anti-pVHL(30)/pVHL(19)) and against pVHL(30) (anti-pVHL(30); Ig33) were used. The anti-pVHL(30)/pVHL(19) antibody showed nuclear and cytoplasmic pVHL expression, whereas the anti-pVHL(30) antibody (Ig33) detected cytoplasmic pVHL expression, suggesting that the distribution of VHL protein isoforms varies in the nuclear and cytoplasmic compartments of renal tumors. There were 175 of 398 primary clear-cell RCCs (44%) with both nuclear and cytoplasmic pVHL expression. Seventy-seven clear-cell RCCs (19%) showed only nuclear, 22 (6%) showed only cytoplasmic, and 124 tumors (31%) showed no pVHL expression. Notably, combined nuclear and cytoplasmic pVHL expression was associated with low histological grade (P < 0.0001), early tumor stage (P < 0.01), and better prognosis (P < 0.01). These results imply that alteration of subcellular pVHL trafficking is of potential relevance for the biological behavior of clear-cell RCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937142      PMCID: PMC1868278          DOI: 10.1016/s0002-9440(10)63461-x

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors.

Authors:  H Moch; T Gasser; M B Amin; J Torhorst; G Sauter; M J Mihatsch
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade.

Authors:  A Nocito; L Bubendorf; E M Tinner; K Süess; U Wagner; T Forster; J Kononen; A Fijan; J Bruderer; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; M Anabitarte; F Hering; T Hardmeier; A J Schoenenberger; R Flury; P Jäger; J L Fehr; P Schraml; H Moch; M J Mihatsch; T Gasser; G Sauter
Journal:  J Pathol       Date:  2001-07       Impact factor: 7.996

3.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

5.  VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.

Authors:  M Velickovic; B Delahunt; S Störkel; S K Grebem
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

6.  Molecular evidence for derivation of metastatic cells from minor subclones of primary clear renal cell carcinomas.

Authors:  J Gronwald; P Hadaczek; S Störkel; H Holtgreve-Grez; P Rabbitts; T Cremer; J Lubinski
Journal:  Cancer Detect Prev       Date:  1999

7.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

Authors:  R Simon; A Nocito; T Hübscher; C Bucher; J Torhorst; P Schraml; L Bubendorf; M M Mihatsch; H Moch; K Wilber; A Schötzau; J Kononen; G Sauter
Journal:  J Natl Cancer Inst       Date:  2001-08-01       Impact factor: 13.506

8.  Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.

Authors:  K Tanimoto; Y Makino; T Pereira; L Poellinger
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

9.  Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma.

Authors:  P Schraml; D Müller; R Bednar; T Gasser; G Sauter; M J Mihatsch; H Moch
Journal:  J Pathol       Date:  2000-03       Impact factor: 7.996

10.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.

Authors:  H Brauch; G Weirich; J Brieger; D Glavac; H Rödl; M Eichinger; M Feurer; E Weidt; C Puranakanitstha; C Neuhaus; S Pomer; W Brenner; P Schirmacher; S Störkel; M Rotter; A Masera; N Gugeler; H J Decker
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

View more
  9 in total

1.  Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?

Authors:  Adriana von Teichman; Martina Storz; Susanne Dettwiler; Holger Moch; Peter Schraml
Journal:  Virchows Arch       Date:  2012-09-25       Impact factor: 4.064

2.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Authors:  Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

3.  Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance.

Authors:  Shin-Ichiro Maruya; Hyung-Woo Kim; Randal S Weber; Jack J Lee; Merril Kies; Mario A Luna; John G Batsakis; Adel K El-Naggar
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

Review 4.  [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].

Authors:  H Moch
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

5.  Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.

Authors:  Caroline Razafinjatovo; Svenja Bihr; Axel Mischo; Ursula Vogl; Manuela Schmidinger; Holger Moch; Peter Schraml
Journal:  BMC Cancer       Date:  2016-08-17       Impact factor: 4.430

6.  Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium.

Authors:  Hisashi Hasegawa; Yoshiaki Kusumi; Takeshi Asakawa; Miyoko Maeda; Toshinori Oinuma; Tohru Furusaka; Takeshi Oshima; Mariko Esumi
Journal:  BMC Cancer       Date:  2017-05-26       Impact factor: 4.430

7.  Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors.

Authors:  Giovanni Minervini; Raffaele Lopreiato; Raissa Bortolotto; Antonella Falconieri; Geppo Sartori; Silvio C E Tosatto
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

8.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

9.  Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Juana Dornbusch; Aristeidis Zacharis; Matthias Meinhardt; Kati Erdmann; Ingmar Wolff; Michael Froehner; Manfred P Wirth; Stefan Zastrow; Susanne Fuessel
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.